Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model

Biochemical Pharmacology

Volumn 67, Issue 10, 2004, Pages 1997-2004

  St Pierre, Philippe ^a   Bouffard, Lucie ^a   Maheux, Pierre ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Fructose fed rat model; Insulin resistance; Microcirculation; Nitric oxide synthase; Rosiglitazone; Skeletal muscle; Thiazolidinediones; Vascular permeability

Indexed keywords

DRUG VEHICLE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EVANS BLUE; FRUCTOSE; INSULIN; ISOENZYME; ROSIGLITAZONE; TRIACYLGLYCEROL; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; EXTRAVASATION; FEEDING; GASTROCNEMIUS MUSCLE; HEMOCONCENTRATION; IMMUNOREACTIVITY; IN VIVO STUDY; INSULIN BLOOD LEVEL; KIDNEY; LUNG; MACROMOLECULE; MALE; MASS; MEAN ARTERIAL PRESSURE; MODEL; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RAT; RECTUS FEMORIS MUSCLE; SKELETAL MUSCLE; SOLEUS MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; VASTUS LATERALIS MUSCLE;

ANIMALS; BODY WEIGHT; CAPILLARY PERMEABILITY; DIETARY CARBOHYDRATES; DRUG INTERACTIONS; FRUCTOSE; HYPOGLYCEMIC AGENTS; MALE; MUSCLE, SKELETAL; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2342474559     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.02.008     Document Type: Article

References (41)

1. Egan B.M., Greene E.L., Goodfriend T.L. Insulin resistance and cardiovascular disease. Am. J. Hypertens. 14(Suppl. 1):2001;116S-125S
2. DeFronzo R.A., Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diab. Care. 14:1991;173-194
3. Maheux P., Jeppesen J., Sheu W.H.-H., Hollenbeck C.B., Clinkingbeard C., Greenfield M.S., et al. Additive effects of obesity, hypertension and type 2 diabetes on insulin resistance. Hypertension. 24:1994;695-698
4. Sowers J.R., Standley P.R., Ram J.L., Jacober S., Simpson L., Rose K. Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am. J. Hypertens. 6:1993;260S-270S
5. Harano Y., Suzuki M., Koyama Y., Kanda M., Yasuda S., Suzuki K., et al. Multifactorial insulin resistance and clinical impact in hypertension and cardiovascular diseases. J. Diab. Compl. 16:2002;19-23
6. Fontbonne A., Charles M.A., Thibult N., Richard J.L., Claude J.R., Warnet J.M., et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia. 34:1991;356-361
7. Calles-Escandon J., Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. 22:2001;36-52
8. Tooke J.E., Hannemann M.M. Adverse endothelial function and the insulin resistance syndrome. J. Intern. Med. 247:2000;425-431
9. Sjostrand M., Gudbjornsdottir S., Holmang A., Lonn L., Strindberg L., Lonnroth P. Delayed transcapillary transport of insulin to muscle interstitial fluid in obese subjects. Diabetes. 51:2002;2742-2748
10. Chakir M., Plante G.E., Maheux P. Reduction of capillary permeability in the fructose-induced hypertensive rat may be responsible for the insulin resistance phenomenon. Am. J. Hypertens. 11:1998;563-569
11. Plante G.E., Perreault M., Lanthier A., Marette A., Maheux P. Reduction of endothelial NOS and bradykinin-induced extravasation of macromolecules in skeletal muscle of the fructose-fed rat model. Cardiovasc. Res. 59:2003;963-970
12. Petersen K.F., Shulman G.I. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am. J. Cardiol. 90(Suppl.):2002;11G-18G
13. Clark M.G., Rattigan S., Clerk L.H., Vincent M.A., Clark A.D.H., Youd J.M., et al. Nutritive and non-nutritive blood flow: rest and exercise. Acta Physiol. Scand. 168:2000;519-530
14. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 287:2002;360-372
15. Raji A., Seely E.W., Bekins S.A., Williams G.H., Simonson D.C. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diab. Care. 26:2003;172-178
16. Bakris G., Viberti G., Weston W.M., Heise M., Porter L.E., Freed M.I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J. Hum. Hypertens. 17:2003;7-12
17. Green D.J., O'Driscoll G., Blanksby B.A., Taylor R.R. Control of skeletal muscle blood flow during dynamic exercise: contribution of endothelium-derived nitric oxide. Sports Med. 21:1996;119-146
18. Stamler J.S., Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol. Rev. 81:2001;209-237
19. Yamakawa K., Hosoi M., Koyama H., Tanaka S., Fukumoto S., Morii H., et al. Peroxisome proliferator-activated receptor gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 271:2000;571-574
20. Emoto M., Anno T., Sato Y., Tanabe K., Okuya S., Tanizawa Y., et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes. 50:2001;1166-1170
21. Baba T., Shimada K., Neugebauer S., Yamada D., Hashimoto S., Watanabe T. The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diab. Care. 24:2001;953-954
22. Tanimoto T., Jin Z.G., Berk B.C. Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J. Biol. Chem. 277:2002;42997-43001
23. Jozkowicz A., Cooke J.P., Guevara I., Huk I., Funovics P., Pachinger O., et al. Genetic augmentation of nitric oxide synthase increases the vascular generation of VEGF. Cardiovasc. Res. 51:2001;773-783
24. Sirois M.G., Plante G.E., Braquet P., Sirois P. Role of eicosanoids in PAF-induced increases of the vascular permeability in rat airways. Br. J. Pharmacol. 101:1990;896-900
25. Plante G.E., Bissonnette M., Sirois M.G., Regoli D., Sirois P. Renal permeability alteration precedes hypertension and involves bradykinin in the spontaneously hypertensive rat. J. Clin. Invest. 89:1992;2030-2032
26. 2 receptor activation elicits organ-specific increases in microvascular permeability in the rat. Am. J. Physiol. 268:1995;R366-R374
27. Rogers D.F., Boschetto P., Barnes P.J. Correlation between Evans Blue dye and radiolabeled albumin in guinea pig aiways in vivo. J. Pharmacol. Methods. 21:1989;309-315
28. Ariano M.A., Armstrong R.B., Edgerton V.R. Hindlimb muscle fiber populations of five mammals. J. Histochem. Cytochem. 21:1973;51-55
29. Patterson C.E., Rhoades R.A., Garcia J.G. Evans Blue dye as a marker of albumin clearance in cultured endothelial monolayer and isolated lung. J. Appl. Physiol. 72:1992;865-873
30. Kapur S., Bédard S., Marcotte B., Côté C.H., Marette A. Expression of nitric oxide as a modulator of insulin action. Diabetes. 46:1997;1691-1700
31. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 108:2003;2941-2948
32. Idris I., Gray S., Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia. 46:2003;288-290
33. Vincent M.A., Barrett E.J., Lindner J.R., Clark M.G., Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am. J. Physiol. 285:2003;E123-E129
34. Kubes P. Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. Microcirculation. 2:1995;235-244
35. Marx N., Bourcier T., Sukhova G., Libby P., Plutzky J. PPAR gamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR gamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19:1999;546-551
36. Fukunaga Y., Itoh H., Doi K., Tanaka T., Yamashita J., Chun T.H., et al. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis. 158:2001;113-119
37. Hattori Y., Hattori S., Kasai K. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. Hypertension. 33:1999;943-948
38. Uchida K., Ogino K., Shimoyama M., Hisatome I., Shigemasa C. Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts. Eur. J. Pharmacol. 400:2000;113-119
39. Arima S., Kohagura K., Takeuchi K., Taniyama Y., Sugawara A., Ikeda Y., et al. Biphasic vasodilator action of troglitazone on the renal microcirculation. J. Am. Soc. Nephrol. 13:2002;342-349
40. Panigrahy D., Singer S., Shen L.Q., Butterfield C.E., Freedman D.A., Chen E.J., et al. PPARg ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 110:2002;923-932
41. Murata T., Hata Y., Ishibashi T., Kim S., Hsueh W.A., Law R.E., et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch. Opthalmol. 119:2001;709-717